



HAL
open science

Extended extraocular phenotype of PROM1 mutation in kindreds with known autosomal dominant macular dystrophy

Sanjay M Sisodiya, Francesca I Arrigoni, Mar Matarin, Pam J Thomson, Mike Michaelides, Michael McClements, Elisabeth Redmond, Lindsay Clarke, E Ellins, S Mohamed, et al.

► To cite this version:

Sanjay M Sisodiya, Francesca I Arrigoni, Mar Matarin, Pam J Thomson, Mike Michaelides, et al.. Extended extraocular phenotype of PROM1 mutation in kindreds with known autosomal dominant macular dystrophy. *European Journal of Human Genetics*, 2010, 10.1038/ejhg.2010.147. hal-00578712

HAL Id: hal-00578712

<https://hal.science/hal-00578712>

Submitted on 22 Mar 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Extended extraocular phenotype of *PROM1* mutation in kindreds with known autosomal dominant macular dystrophy

FI Arrigoni^{1,2*}, M Matarin^{3*}, PJ Thompson³, M Michaelides^{4,5}, ME McClements⁴, E Redmond¹, L Clarke¹, E Ellins¹, S Mohamed³, I Pavord⁶, DM Hunt⁴, N Klein⁷, AT Moore^{4,5}, J Halcox^{1,8}, SM Sisodiya³

¹Vascular Physiology, UCL Institute of Child Health, 30 Guilford Street, London, WC1N 1EH;

²Department of Pharmacy, Kingston University, Penrhyn Road, KT1 2EE, ³Department of

Clinical and Experimental Epilepsy, UCL Institute of Neurology, Queen Square, London WC1N

3BG and National Society for Epilepsy, Bucks, SL9 0RJ; ⁴UCL Institute of Ophthalmology, 11-

43 Bath Street, London EC1V 9EL; ⁵Moorfields Eye Hospital, City Road, London, EC1V 2PD,

UK; ⁶Department of Respiratory Medicine, Allergy and Thoracic Surgery, Institute for Lung

Health, Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester LE3 9QP,

UK; ⁷Research Department of Infection, UCL Institute of Child Health, 30 Guilford Street

London WC1N 1EH, and ⁸Wales Heart Research Institute, Cardiff University, Cardiff, UK

* These authors contributed equally

Author for Correspondence:

SM Sisodiya, Department of Clinical and Experimental Epilepsy, National Hospital for Neurology and Neurosurgery, Box 29, Queen Square, London, UK WC1N 3BG

Tel 020 7391 8983

Fax 020 7391 8984

Email: sisodiya@ion.ucl.ac.uk

Running Head: Extended *PROM1* phenotype

Key words: *PROM1*, CD 133, endothelial, tubule, sella turcica

Total Word Count: 3,019 (max 4,000)

Abstract text: 146 (max 250)

Tables and Illustrations: 3 figures and 3 tables (max 6)

Table1: Cognitive performance and plus

Table 2: Baseline characteristics

Table 3: Microparticles

Figure 1: Leucoaraiosis and empty sella turcica

Figure 2: Representative micrograph of HUVEC

Figure 3: Angiogenesis assay between HUVEC and ECFCs.

References: 42 plus 10 in supplementary material (max 50)

Supplementary material: 1,733

Abstract

Mutations in prominin 1 (*PROM1*) have been shown to result in retinitis pigmentosa, macular degeneration and cone-rod dystrophy. Because of the putative role of *PROM1* in hippocampal neurogenesis, we examined two kindreds with the same R373C *PROM1* missense mutation using our established paradigm to study brain structure and function. As the protein encoded by *PROM1*, known as CD133, is used to identify stem/progenitor cells that can be found in peripheral blood and reflect endothelial reparatory mechanisms, other parameters were subsequently examined that included measures of vascular function, endothelial function and angiogenic capacity. We found that aspects of endothelial function assayed ex vivo were abnormal in patients with the R373C *PROM1* mutation, with impaired adhesion capacity and higher levels of cellular damage. We noted also renal infections, haematuria and recurrent miscarriages possibly reflecting consequences of abnormal tubular modelling. Further studies are needed to confirm these findings.

Introduction

The effects of a single human gene mutation may be widespread and, in their breadth, often unsuspected. We have previously explored the cerebral structural and functional effects of mutations in genes expressed in the eye and the brain, in individuals ascertained by their mutant eye phenotype, in whom extraocular phenotypes were often not appreciated. Using this paradigm, we have demonstrated roles for the genes *PAX6*, *PITX2*, *SOX2*, *OTX2* and *RIMS1* in human brain development, and cognitive function [1- 4].

Mutations in prominin 1 (*PROM1*) have been shown to result in retinitis pigmentosa [5, 6] macular degeneration [7, 8] and cone-rod dystrophy [9]. *PROM1* encodes prominin-1, a 5-transmembrane glycoprotein also known as CD133 and AC133. CD133 was originally identified as a cell surface antigen present on hematopoietic stem cells and early progenitor cells in the bone marrow, including endothelial progenitor cells (EPC) [10, 11].

Emerging evidence suggests that EPCs are able to differentiate into mature endothelial cells, contributing to neovascularization and re-endothelialization during both embryonic and postnatal physiological processes [12]. Consequently, CD133 is used to identify stem/progenitor cells that can be found in peripheral blood and thereby identify endothelial reparatory mechanisms and also to identify tumour stem cell populations in a variety of blood and solid cancers [13, 14]. Consistent with a role in tissue repair, increased levels of circulating early EPCs marked by CD133 have also been found in response to brain injury [15]. CD133 is also involved in murine and human adult hippocampal neurogenesis [16], murine brain myelin genesis and maintenance [17]

Because of the putative role of *PROM1* in hippocampal neurogenesis, we examined two kindreds with the same known *PROM1* mutation using our established paradigm to study brain structure and function. We subsequently examined other parameters including measures of vascular function, endothelial function and angiogenic capacity.

Methods

The study included two unrelated kindreds that were already reported as having autosomal dominant macular degeneration mapped to 4 p15.2-16.3 [5, 18]. From kindred A, the proband (A-V:1), her mother (A-IV:2), aunt (A-IV:4) and grandmother (A-III:6) were studied. In kindred B, the proband (B-II:1) and her mother (B-I:1) were included in the study (Table 1). In both probands, the same R373C *PROM1* mutation had been identified. Clinical history was obtained from all participants.

Healthy control groups were recruited from staff and colleagues from the Institute of Child Health.

The study was approved by the Joint Research Ethics Committees of the Institute of Neurology/ National Hospital for Neurology and Neurosurgery, and Moorfields Eye Hospital and the Institute of Child Health/Great Ormond Street Hospital for Children NHS Foundation Trust. Subjects provided informed written consent for all parts of the study.

Brain imaging

Subjects were studied on a 3T scanner. Details of the high-resolution MRI, cerebral and hippocampal volumetry are provided in the Supplementary material.

Cognitive tests applied to kindreds

Neuropsychological tests employed were as described previously [19]. All of the standardised tests selected require verbal interaction only. Intellectual level, executive and memory function were tested. Details are given in the Supplementary Material.

Clinical testing

Proband A-V:1 had renal and pulmonary assessments previously undertaken due to relevant clinical symptoms. Olfactory testing was undertaken using the UPSIT [1] (Sensonics Inc., Haddon Heights, NJ), with age-matched control data based upon North American subjects, shown to be applicable to British populations [20, 21].

Blood and vascular investigations

After a 12-hour overnight fast, venous blood was taken from three subjects from kindred A, and one from kindred B. After subjects had rested for >15 minutes, recumbent

right brachial artery blood pressure was recorded using an automated sphygmomanometer (Dinamap, Critikon, Florida, USA). Five readings were taken and mean systolic and diastolic blood pressure calculated.

The isolation of peripheral blood mononuclear cells (PBMCs), flow cytometric analysis for detection of EPCs and cellular microparticles, circulating endothelial cell extraction and analyses, growth factor detection, the ability of specific cells to form colonies, microparticle assays and *in vitro* colony forming and matrigel angiogenesis assays were performed as detailed in the Supplementary Material. For kindred A, vascular structure (carotid artery intima-media thickness, IMT) and function (flow-mediated dilatation of brachial artery, FMD) were also assessed (Supplementary Material).

Statistics

Nonparametric tests (U-Mann-Whitney) were used with SPSS, version 14 (SPSS Inc). Data were expressed as median and interquartile range.

Results

Clinical findings

The ocular phenotypic data have been published [5, 18]. A-V:1 had steroid-resistant asthma. She had a clinical assessment for microscopic haematuria, with a normal renal ultrasound and intravenous pyelogram. A-IV:2 also had microscopic haematuria, with recurrent renal infection, and renal scarring on intravenous pyelography. She had eight pregnancies, and four children. A-III:6 had recurrent renal infections, seven pregnancies with three miscarriages, and four children. A-IV:4 had two unprovoked seizures.

In kindred B, B-I:1 had high blood pressure and high cholesterol.

According to North-American normative data UPSIT A-IV:4 and B-II:1 had mild microsmia and A-III:6 had moderate microsmia.

Neuroimaging

Subject A-III:6 had many small high-intensity lesions in the cerebral white matter (Fig 1B). Subjects A-IV:4 and B-I:1 also had a few (1-2) non-specific white matter (WM) lesions. The presence of WM hyperintensities on the FLAIR images for subject A-III:6 was scored by a radiologist blind to the clinical data, using the Scale of Tarvonen-Schroder and Scheltens semiquantative rating scale [22]. This scale scores the severity of hyperintensities separately in different anatomical areas of the brain including periventricular regions, areas of deep white matter, basal ganglia and different infratentorial regions. The total score was 19. Lesions were focused on deep white matter (score=16/24) and pons (score=3/6). Lesions in frontal brain area were considered as severe and mild to moderate in the other brain areas.

An empty sella turcica was noted in A-III:6, A-IV:2 and A-IV:4 (Fig 1A). Baseline pituitary function (TSH, T4, cortisol, FSH and LH) was normal in all three. No other changes were noted. MRI brain scans in kindred B were normal. Hippocampal and cerebral volumes were within normal ranges for all patients from both kindreds.

Cognitive function

No distinctive pattern of cognitive deficit was noted (Table 1). All subjects in kindred A except A-IV:4 showed average to superior verbal memory scores. A-IV:4 showed poor performance for delayed recall on the auditory verbal learning test with an average performance on the remaining tests of memory. In kindred B, B-I:1 had impaired verbal learning for trials, reduced performance on tests of immediate recall and delayed verbal learning. All subjects except A-IV:4 and B-I:1 showed average executive functions.

Vascular and endothelial function

Vascular profiles

Subjects A-V:1, A-IV:2 and A-III:6 underwent vascular investigation. Each subject was ranked into an age group, (1, 2 or 3), in which 12 healthy controls, with a median age similar to that of the subject, were included (see Table 2). Patients and controls were all female and had no known cardiovascular risk factors with the exception of high blood pressure and high cholesterol in subject B-1:1.

Brachial artery FMD and carotid artery IMT

Detailed descriptions of procedures are in Supplementary Material. Briefly the diameter of the brachial artery was measured at rest, during reactive hyperaemia to induce flow-mediated endothelium-dependent dilation (FMD), again at rest, and after administration of GTN, an endothelium-independent dilator. FMD and the ratio FMD:GTN-induced dilatation provide the best measures of endothelial function.

Flow-mediated dilatation did not alter with age in the controls (Table 1). There was no difference in median FMD when comparing grouped controls and patients (8.28 (5.68-11.40) and 4.88 (4.06-12.27)). The ratio FMD:GTN did not alter with age in controls, but fell with age in the patients. The median FMD:GTN ratio for the grouped patients did not differ from the controls (0.95 (0.90-0.97) and 0.98 (0.96-1.02)). Intima-media thickness (IMT) increased significantly with age in the controls (Table 2). Increasing IMT values were also observed in the patients. However, there was no difference in the median values for IMT between grouped controls and PROM-1 patients (0.65 (0.58-0.72) and 0.52 (0.48-0.75)).

Determination of Growth Factor Concentration

Angiotensin-2 levels and vascular endothelial growth factor (VEGF) levels were within the normal range according to established clinical ranges.

Isolation and quantification of EPC

In controls, circulating endothelial cell (CEC) number significantly increased between the younger groups 1 and 2, but not between either of the other age groups (Table 2). Increase of CECs with age is less evident in PROM1 patients but falls within ranges for healthy age-matched controls (Table 2). No change in the expression of surface markers was observed with age in controls or PROM1 patients. Calculated as a percentage of the lymphocyte gate, there was no significant difference between groups in the expression of any of the surface markers alone or in combination (Table 2).

Cultivation of EPC

Colony-forming unit endothelial cells (CFU-EC) fell with age in controls. This trend was also observed in the few PROM1 patients. Colony number tended to be low but values fell within the normal range for their ages (controls, 20.37 (7.05- 32.57) and PROM1 patients, 11.9 (4.6-41)).

Relationship Between Cellular and Vascular Measures

Numbers of CFU-EC correlated with FMD:GTN ratio in the controls ($r=0.42$, $p<0.05$). CFU-EC from PROM1 patients demonstrated a similar trend (Supplementary Material).

Microparticle number.

Total microparticle number, which consisted of endothelial microparticles (CD144, D105 and CD62e), platelet microparticles (CD42a) and monocyte-derived microparticles (CD14), fell within the upper range in PROM1 patients in relation to age-matched controls. Comparisons between patients and controls independently to age, showed higher number of total microparticles in PROM-1 patients ((2.606(1.399- 2.97); 0.3023(0.14-1.35) for PROM-1 patients and healthy age matched controls respectively, median \pm interquartile range, $p=$

0.0028). Furthermore endothelial microparticles defined by CD144 expression were also found to be significantly elevated in the PROM-1 progeny (Table 3).

Angiogenic capability

A Matrigel assay was used to determine the effect of colony-forming unit endothelial cells labelled with acetylated low-density lipoprotein (DiI-acLDL) on HUVEC growth.

DiI-acLDL-labelled cells from PROM1 patients did not adhere to or incorporate into the human umbilical endothelial cells (HUVEC) as well as their age-matched controls (5.6 (0-18); 26.7 (15.5-44.3), $p=0.03$; Figure 3). Furthermore, a lack of DiI-acLDL-labelled cell incorporation into the HUVEC tubules tended to produce lower tubule length in PROM1 subjects when compared to their age-matched controls (0.8 (0.74-1.2) and 1.38 (0.9-1.46), $p=0.06$). No difference in tubule number was observed between the two groups (1 (1-1.14); 0.88(0.52-1.22), $p=0.57$; Figure 3).

Discussion

We describe vascular and endothelial function in addition to cerebral structure and function in two independent families with the same R373C mutation in the *PROM1* gene. Carriers of the mutation were already reported to present clinical features of autosomal dominant macular dystrophy [7, 18].

Human *PROM1* is expressed by various stem and progenitor cells originating from diverse sources [23]. Due to the role of EPC in vascular and endothelial function [24], we investigated these characteristics in five carriers of the R373C mutation. We found that the number of circulating endothelial cells, endothelial markers such as CD133, as well as the ability of EPC to form endothelial colonies fell within the normal range in the tested patients. Endothelium-dependent and endothelium-independent function assessed by FMD and the FMD:GTN ratio did not differ from controls. There was also no difference in intima-media thickness. The basic function and EPC regenerative resources would seem unaffected by the R373C mutation.

However the number of circulating microparticles (MPs) was raised in patients compared to controls. MPs are membrane fragments shed by cells which have been activated by a variety of stimuli including serine proteases, inflammatory cytokines, growth factors and stress inducers [25]. Clinical studies have revealed elevated plasma levels of MPs in multiple sclerosis, thrombotic thrombocytopenic purpura, coronary artery disease, hypertension, preeclampsia, and diabetes [26, 27]. Such data have led to the concept that endothelial MP are key factors at the crossroads between inflammation, coagulation, proteolysis and vascular repair [28]. Elevated circulating levels of MPs in our patients could be an indicator of either platelet, endothelial or leukocyte activation and could reflect a persistent state of endothelial dysfunction.

We looked also at the contribution of immature ECFCs to tubule growth, of immature ECFCs. A significantly decreased ability of these cells to incorporate or adhere to the HUVEC was observed in carriers of the mutation. As this assay evaluates multiple cellular

processes involved in blood vessel growth, EPC functional activity would appear impaired by the mutation. In turn, vascularization might be affected in the patients, at least under certain circumstances, perhaps those requiring neogenesis or repair.

Notably, the mutation carriers had microhaematuria and/or renal infections and a high number of miscarriages. Although there is no study reporting endothelial dysfunction in patients with hematuria and/or renal infections, several studies have reported that EPCs are numerically and functionally impaired in patients with acute [29] or chronic renal failure [30], as compared to healthy subjects and mechanisms such as inflammation or uraemic toxins have been given as potential explanations for the observed EPC dysfunction [30]. More clear and direct is the relationship between miscarriages and possible endothelial dysfunction, given that development, maturation and maintenance of a neovascular network are necessary for successful haemochorial placentation as well as normal embryonic development and growth [31]. Impairment in EPC functionality could thus affect placental angiogenesis and contribute to history of recurrent miscarriages in our patients. This requires further study in a larger group of patients, and might merit study in women with unexplained recurrent miscarriages.

CD133 has been also reported to mark several cell types with a variety of putative roles, including involvement in hippocampal neurogenesis [16, 17] and diverse haematopoietic and extra-haematopoietic progenitive and regenerative functions [32-34]. Carriers of the *PROM1* mutation showed hippocampal and cerebral volumes within normal ranges for all patients from both kindreds. Three patients had small lesions in white matter. Interestingly the presence of MPs has been also reported to be positively associated with contrast-enhancing lesions on brain MRI in subjects with multiple sclerosis [35] and furthermore endothelial dysfunction is thought to play an important role in the pathogenesis of cerebral small-vessel disease especially in those patients with concomitant silent lacunar infarcts and ischemic white matter lesions [36]. In line with this possible accelerated aging effect, the older member from the kindred B and one carrier of the *PROM1* mutation in family A showed some memory disturbance and impairment in measures of executive functions in addition to small WM lesions. The remaining carriers in both families had average IQs and unimpaired performance on the other cognitive measures.

The three (of four) members of family A showed an empty sella turcica. The familial empty sella together with an eye phenotype could suggest a developmental defect of mesenchymal origin caused by mutation in the same gene [37]. Familial empty sella has not, to our knowledge, been reported previously. Three patients had impaired olfaction.

All together, the elevated plasma levels of MPs, decreased ability of EPC to incorporate into or adhere to tubules, the presence of empty sella turcica as well as leucoaraiosis and cognitive decline in the oldest mutation carriers suggest endothelial dysfunction that could be more pronounced or more evident with age. The R373C mutation results in a stable mutant protein. However, the mutant protein is not only mislocalized in retina, but it also interferes with the action of the normal protein [7] thereby accounting for its dominant mode of inheritance. Though we found no difference in the number of circulating EPCs or numbers of cells expressing CD133, the mutation may impair the function. For example the mutation could render EPCs less effective in the process of angiogenesis or repair of damaged endothelium. Carriers of the R373C mutation showed no obvious greater risk of vascular dysfunction, but structural and functional microcirculation alterations tend to occur during ageing. Functional vascular examination was only undertaken in one of the two older patients as the second declined to take part in this test. Moreover the presence of high blood pressure and high cholesterol, as well as leucoaraiosis [38] could be a sign of vascular alteration. Longitudinal study of more individuals with *PROM1* mutation might be informative.

To our knowledge this is the first study reporting a family with eye phenotype together with empty sella turcica, presence of microhematuria and possible endothelial dysfunction. In the case of the eye phenotype (macular dystrophy) the penetrance was complete although showing differences in severity. Penetrance in the other phenotypes was incomplete. Notable is the fact that none of the members in family B presented extra-ocular features, nor MRI findings (other than a few WM lesions), besides the cognitive decline in the older member, raising the possibility of organ-specific penetrance differences, perhaps related to organ-specific splicing differences of the *PROM1* transcript. *PROM1* transcription regulation is rather complicated and poorly understood: it exhibits extensive splice variation

[39] with tissue-specific distribution [40], and in addition transcripts can be regulated by epigenetic factors, as suggested by experiments with artificial *in vitro* methylation. However we cannot exclude the possibility that mutation in a second gene could be influencing the extra-ocular phenotype in family A, especially the presence of empty sella turcica.

The role of *PROM1* in brain is still unclear. The gene, by itself or in combination with other genes, seems to have a role in the development of the brain, and/or cerebral recovery and repair [17, 41]. The heterozygous mutation studied here results in a stable protein [7] and is perhaps insufficient to completely inhibit its function in the brain. In contrast, recessive mutations arise from either frameshift or nonsense mutations [5, 6] that result in the generation of a premature stop codon and truncated protein [5, 6, 42]. In these cases the homozygous patients display a severe eye phenotype, and polydactyly was also reported in one of the carriers, an additional symptom that confirms the existence of variable penetrance associated with *PROM1*. No other documentation about vascular, endothelial or brain structures was reported.

The nature and size of our study does not permit definitive conclusions but leads to the suggestion that endothelial function may be affected in patients with the *PROM1* R373C mutation, despite the apparently normal levels of EPC. Further studies are needed to confirm these interesting findings that broaden the phenotype of *PROM1* mutation, and inform our understanding of CD133 function.

Acknowledgments

We thank the patients who participated. We are grateful to the Big Lottery Fund, Wolfson Trust and the National Society for Epilepsy for supporting the NSE MRI scanner. The work was supported by a joint grant from the Biomedical Research Centres at UCLH/UCL, Great Ormond Street Hospital for Children/UCL Institute of Child Health, and Moorfields Eye Hospital/UCL Institute of Ophthalmology. This work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health's NIHR Biomedical

Research Centres funding scheme. Drs J. E. Halcox. and F. I. Arrigoni were supported by the British Heart Foundation, Dr E. Redmond by the Coronary Artery Disease Research Association, and Ms M. E. M^cClements by Fight for Sight.

Competing Interest: None declared.

Bibliography

- 1 Sisodiya SM, Free SL, Williamson KA, *et al.* PAX6 haploinsufficiency causes cerebral malformation and olfactory dysfunction in humans. *Nature Genetics* 2001;**28**(3):214-6.
- 2 Idrees F, Bloch-Zupan A, Free SL, *et al.* A novel homeobox mutation in the PITX2 gene in a family with Axenfeld-Rieger syndrome associated with brain, ocular, and dental phenotypes. *American Journal of Medical Genetics Part B, Neuropsychiatric Genetics: the Official Publication of the International Society of Psychiatric Genetics* 2006;**141B**(2):184-91.
- 3 Sisodiya SM, Ragge NK, Cavalleri GL, *et al.* Role of SOX2 mutations in human hippocampal malformations and epilepsy. *Epilepsia* 2006;**47**(3):534-42.
- 4 Henderson RA, Williamson K, Cumming S, *et al.* Inherited PAX6, NF1 and OTX2 mutations in a child with microphthalmia and aniridia. *European Journal of Human Genetics* 2007;**15**(8):898-901.
- 5 Zhang Q, Zulfiqar F, Xiao X, *et al.* Severe retinitis pigmentosa mapped to 4p15 and associated with a novel mutation in the PROM1 gene. *Human Genetics* 2007;**122**(3-4):293-9.
- 6 Maw MA, Corbeil D, Koch J, *et al.* A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. *Human Molecular Genetics* 2000;**9**(1):27-34.
- 7 Yang Z, Chen Y, Lillo C, *et al.* Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice.[see comment]. *Journal of Clinical Investigation* 2008;**118**(8):2908-16.
- 8 Permanyer J, Navarro R, Friedman J, *et al.* A novel mutation in PROM1 that results in nonsense mediated decay causes autosomal recessive Retinitis Pigmentosa with early macular affection. *Investigative Ophthalmology & Visual Science* 2010;**51**(5):2656-63.
- 9 Michaelides M, Gaillard M, Escher P, *et al.* The PROM1 mutation p.R373C causes an autosomal dominant bull's eye maculopathy associated with rod, rod-cone and macular dystrophy. *Investigate Ophthalmology and Visual Science* 2010; **[In Press]**.
- 10 Yin AH, Miraglia S, Zanjani ED, *et al.* AC133, a novel marker for human hematopoietic stem and progenitor cells. *Blood* 1997;**90**(12):5002-12.
- 11 Miraglia S, Godfrey W, Yin AH, *et al.* A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. *Blood* 1997;**90**(12):5013-21.
- 12 Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. *Circulation Research* 2004;**95**(4):343-53.
- 13 Singh SK, Hawkins C, Clarke ID, *et al.* Identification of human brain tumour initiating cells.[see comment]. *Nature* 2004;**432**(7015):396-401.
- 14 Zhu L, Gibson P, Curre DS, *et al.* Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation.[see comment]. *Nature* 2009;**457**(7229):603-7.
- 15 Liu L, Liu H, Jiao J, *et al.* Changes in circulating human endothelial progenitor cells after brain injury.[erratum appears in J Neurotrauma. 2007 Aug;24(8):1415 Note: Jao, Junfeng [corrected to Jiao, Junfeng]. *Journal of Neurotrauma* 2007;**24**(6):936-43.

- 16 Kempermann G, Chesler EJ, Lu L, *et al.* Natural variation and genetic covariance in adult hippocampal neurogenesis. *Proceedings of the National Academy of Sciences of the United States of America* 2006;**103**(3):780-5.
- 17 Corbeil D, Joester A, Fargeas CA, *et al.* Expression of distinct splice variants of the stem cell marker prominin-1 (CD133) in glial cells. *GLIA* 2009;**57**(8):860-74.
- 18 Michaelides M, Johnson S, Poulson A, *et al.* An autosomal dominant bull's-eye macular dystrophy (MCDR2) that maps to the short arm of chromosome 4. *Investigative Ophthalmology & Visual Science* 2003;**44**(4):1657-62.
- 19 Sisodiya SM, Thompson PJ, Need A, *et al.* Genetic enhancement of cognition in a kindred with cone-rod dystrophy due to RIMS1 mutation. *Journal of Medical Genetics* 2007;**44**(6):373-80.
- 20 Gibberd FB, Feher MD, Sidey MC, *et al.* Smell testing: an additional tool for identification of adult Refsum's disease. *Journal of Neurology, Neurosurgery & Psychiatry* 2004;**75**(9):1334-6.
- 21 Silveira-Moriyama L, Petrie A, Williams DR, *et al.* The use of a color coded probability scale to interpret smell tests in suspected parkinsonism. *Movement Disorders* 2009;**24**(8):1144-53.
- 22 Scheltens P, Barkhof F, Leys D, *et al.* A semiquantitative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging *Journal of the Neurological Sciences* 1993;**114**:7-12.
- 23 Wu Y, Wu P. CD133 as a marker for cancer stems cells: progresses and concerns. *Stem Cells and Development* 2009(May 2).
- 24 Werner N, Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy? *Arteriosclerosis, Thrombosis & Vascular Biology* 2006;**26**(2):257-66.
- 25 Doeuvre L, Plawinski L, Toti F, *et al.* Cell-derived microparticles: a new challenge in neuroscience. *Journal of Neurochemistry* 2009;**110**(2):457-68.
- 26 Morel O, Toti F, Hugel B, *et al.* Procoagulant microparticles: disrupting the vascular homeostasis equation? *Arteriosclerosis, Thrombosis & Vascular Biology* 2006;**26**(12):2594-604.
- 27 Chironi GN, Boulanger CM, Simon A, *et al.* Endothelial microparticles in diseases. *Cell & Tissue Research* 2009;**335**(1):143-51.
- 28 Sabatier F, Camoin-Jau L, Anfosso F, *et al.* Circulating endothelial cells, microparticles and progenitors: key players towards the definition of vascular competence. *Journal of Cellular and Molecular Medicine* 2009;**13**(3):454-71.
- 29 Westerweel PE, Hoefler IE, Blankestijn PJ, *et al.* End-stage renal disease causes an imbalance between endothelial and smooth muscle progenitor cells. *American Journal of Physiology - Renal Physiology* 2007;**292**(4):F1132-40.
- 30 Herbrig K, Pistrosch F, Foerster S, *et al.* Endothelial progenitor cells in chronic renal insufficiency. *Kidney & Blood Pressure Research* 2006;**29**(1):24-31.
- 31 Demir R, Seval Y, Huppertz B. Vasculogenesis and angiogenesis in the early human placenta. *Acta Histochemica* 2007;**109**(4):257-65.
- 32 Urbich C, Dimmeler S. Endothelial progenitor cells functional characterization. *Trends in Cardiovascular Medicine* 2004;**14**(8):318-22.
- 33 Zeppernick F, Ahmadi R, Campos B, *et al.* Stem cell marker CD133 affects clinical outcome in glioma patients. *Clinical Cancer Research* 2008;**14**(1):123-9.

- 34 Cantley LG. Adult stem cells in the repair of the injured renal tubule. *Nature Clinical Practice Nephrology* 2005;**1**(1):22-32.
- 35 Minagar A, Jy W, Jimenez JJ, *et al.* Elevated plasma endothelial microparticles in multiple sclerosis. *Neurology* 2001;**56**(10):1319-24.
- 36 Knottnerus IL, Ten Cate H, Lodder J, *et al.* Endothelial dysfunction in lacunar stroke: a systematic review. *Cerebrovascular Diseases* 2009;**27**(5):519-26.
- 37 Asahara T, Masuda H, Takahashi T, *et al.* Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. *Circulation Research* 1999;**85**(3):221-8.
- 38 Brown WR, Moody DM, Thore CR, *et al.* Microvascular changes in the white matter in dementia. *Journal of the Neurological Sciences* 2009;**283**(1-2):28-31.
- 39 Fargeas CA, Huttner WB, Corbeil D. Nomenclature of prominin-1 (CD133) splice variants - an update. *Tissue Antigens* 2007;**69**(6):602-6.
- 40 Pleshkan VV, Vinogradova TV, Sverdlov ED. Methylation of the prominin 1 TATA-less main promoters and tissue specificity of their transcript content. *Biochimica et Biophysica Acta* 2008;**1779**(10):599-605.
- 41 Hermann A, Maisel M, Liebau S, *et al.* Mesodermal cell types induce neurogenesis from adult human hippocampal progenitor cells. *Journal of Neurochemistry* 2006;**98**(2):629-40.
- 42 Pras E, Abu A, Rotenstreich Y, *et al.* Cone-rod dystrophy and a frameshift mutation in the PROM1 gene. *Mol Vis* 2009;**15**:1709-16.

R373C <i>PROM1</i> mutation	Family A				Family B	
	Subject	A-III: 6	A-IV: 4	A-IV: 2	A-V: 1	B-I: 1
Relationship to proband	Maternal Grandmother	Maternal Aunt	Mother	Proband	Mother	Daughter
Age	65	41	44	21	65	32
VIQ	114	90	96	110	106	110
Verbal Learning Trials	46 (50th)	46 (25th)	51 (50th)	50 (25th)	22 (<1st)	56 (50th)
Verbal learning delay	7 (25th)	9 (10th)	13 (75th)	12 (50th)	6 (10th)	14 (75th)
Verbal Recall Immediate	38 (75th)	31 (25th)	43 (90th)	49 (90th)	17 (10th)	48 (90th)
Verbal Recall %	105 (90th)	90 (50th)	102 (90th)	98 (90th)	88 (50th)	92 (50th)
Fluency phonemic "s"	12	19	16	18	15	24
Fluency animals	19	15	26	24	20	28
Hayling total score	14	16	13	18	11	17
Cognitive estimates	5	12	8	7	4	5
Extraocular medical history	RI, M,MC	M	MH,RI,MC	SRA,MH,ne	normal	M
MRI findings	WMH,EST	WMH,EST	EST	normal	WMH	normal
Vascular profiles	EX	ne	EX	EX	ne	ne
Endothelial function	EX	ne	EX	EX	ne	EX

Table 1: Summary of age –corrected cognitive performance (in cursive poor or impaired scores) and extraocular findings. VIQ: Verbal Intelligence Quotient EX: Examined; ne: not examined; RI: Renal Infections; MC: Miscarriages; M= Microsmia; MH: Microscopic Haematuria; SRA: Steroid Resistant Asthma; WMH: White Matter Hyperintensities; EST: Empty Sella Turcica.

Age Group	1			2		3		P
ID	A-V:1	B-II:1	Control	A-IV:2	Control	A-III:6	Control	
Age	19	32	21(17-24)	46	46 (45-47)	66	55(53-61)	
Gender	Female			Female		Female		
% FMD	12.27		7.4 (4.5-11.4)	4.06	9.4 (6.1-12)	4.88	7.27 (6.2-11.5)	ns
FMD/NTG	1.02		0.95 (0.9-1)	0.98	0.9 (0.9-1)	0.96	0.95 (0.9-1)	ns
Average IMT (mm)	0.48		0.58 (0.6-0.6)	0.52	0.64# (0.6-0.7)	0.75	0.76 (0.7-0.8)	ns [*#]
Angiopoetin (pg/ml)	1234.2			1030		1838.8		
VEGF (pg/ml)	413.9			643.5		568		
CEC (ml blood)	28	16	32 (15-38)	56	64 (52-78)	48	74 (27-108)	ns [0.04]
CD 133 ⁺	0.05	0.25	0.05 (0-0.03)	0	0.02 (0.02-0.46)	0.03	0.025 (0.02-0.6)	ns
CD 34 ⁺	0.01	0.17	0.13 (0.06-0.39)	0.2	0.2 (0.12-0.37)	0.2	0.25 (0.05-0.63)	ns
CD 144 ⁺	0.76		0.53 (0.44-1.71)	1.34	0.39 (0.13-1.89)	4.69	1.05 (0.81-2.61)	ns
KDR/CD34 ⁺	0.06	0.07	0.07 (0.06-0.2)	0.02	0.05 (0.02-0.08)	0.05	0.05 (0.03-0.1)	ns
CD144/CD34 ⁺	0.03	0.02	0.03 (0.01-0.21)	0.08	0.025 (0.01-0.05)	0.09	0.025 (0.01-0.05)	ns
Colony number	15.8	41	47.8 (11.1-75.1)	8	14.4 (1.7-25.3)	4.6	17.2 (10.9-22.7)	ns [0.04]

Table 2. Blood/vasculature tests in controls and PROM1 subjects. Values represent median (interquartile range). P values=statistics are for comparisons between patients and controls and []= comparisons within age control groups * p=0.0008, compared to group 1, # p=0.008 compared to group 3; ns: not significant; FMD: Flow-mediated Dilatation; GTN: Glyceryl Trinitrate (25 micrograms); CEC: Circulating Endothelial Cell; IMT : Intima Media Thickness ; VEGF: Vascular Endothelial Growth Factor. ⁺= Surface markers

Age Group	Million microparticles/ml blood								P values
	1			2		3			
	A-V:1	B-II:1	Control	A-IV:2	Control	A-III:6	Control		
Age	19	32	28 (23-31)	46	40 (38-43)	66	64 (61-65)		
CD62e	0.015	0.556	0.009 (0-1.08)	0.086	0.005 (0-0.05)	0.08	0.14 (0.01-0.02)	0.0279	
CD144	1.19	0.774	0.02 (0-0.7)	1.27	0.33 (0.13-0.41)	0.8	0.15 (0.04-0.21)	<i>0.0018</i>	
CD105	0.7	0.085	0.04 (0-0.71)	0.16	0.06 (0.02-0.41)	0.39	0.035 (0.02-0.07)	0.0613	
CD42	0.47	0.56	0.2 (0-0.88)	0.57	0.23 (0.18-0.38)	1.15	0.085 (0.07-1.04)	0.0115	
CD14	2.7	0.7	0.29 (0-1.3)	1.98	0.17 (0.03-0.34)	2.87	0.076 (0.06-0.94)	<i>0.0028</i>	
Total MP number	2.89	1.09	0.28 (0.04-1.35)	2.32	0.51 (0.18-0.55)	3	0.19 (0.17-0.67)	<i>0.0028</i>	

Table 3. Expression of microparticle number in platelet-poor plasma taken from PROM1 subjects. Data expressed as median (range) microparticles per ml of blood or plasma. P = statistics are for comparisons between PROM1 patients and controls. Significant p-values in italics (after Bonferroni correction).

Titles and legends to figures

Figure 1A. The white arrows show empty sella turcica in three PROM1 patients (A-IV:4, A-III:6 and A-IV:2) and one normal sella turcica (A-V:1). **Figure 1B.** The black arrows show White Matter Hyperintensities in one PROM1 patient (A-III:6).

Figure 2. Representative micrograph of HUVEC in Matrigel for 18 hours with EGM-2 grown cells from PROM1 patients and age-matched controls (24, 47 and 61 years old). Cells labelled red are DiI-labelled EGM-2 grown cells after seven days in culture. Fewer adherent (red-coloured) cells and a tendency for shorter tubule formation are apparent in patients compared to controls. The adhesion of the (red-labelled) ECFCs contributes to endothelial tubule formation. Following culture of ECFCs with HUVEC, fewer ECFCs were adherent or incorporated into the tubules from the PROM1 subject when compared to the age matched control. Magnification x100, 8 random fields studied in A-V:1, A-IV:2 and A-III:6 and B-I:1.

Figure 3. Angiogenesis assay for HUVEC and ECFCs.

Alteration in growth of HUVEC tubules with ECFCs from PROM1 subjects.

A. Number of cells adherent/incorporated into endothelial tubules on Matrigel in PROM1 subjects and healthy age-matched controls; **B.** Number of tubules formed on Matrigel plate, averaged over 8 random fields between PROM1 patients and controls. **C.** Average tubule length of HUVEC formed on Matrigel, averaged over 8 random fields, between PROM1 and controls, * $p < 0.05$ significant difference between PROM1 and control group.





